OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

ORION CLASS B/  FI0009014377  /

Euronext Milan (TAH)
2024-07-03  6:00:12 PM Chg. - Volume Bid8:30:00 PM Ask3:00:54 AM Market Capitalization Dividend Y. P/E Ratio
42.820EUR - 10
Turnover: 428.200		 -Bid Size: - -Ask Size: - 5.17 bill.EUR 3.35% 31.37
GlobeNewswire 07-17 Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation...
GlobeNewswire 07-01 Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive ...
GlobeNewswire 06-03 Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire 01-26 Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
GlobeNewswire 01-08 Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...
GlobeNewswire 01-05 Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...
GlobeNewswire 2023-12-27 NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
GlobeNewswire 2023-11-15 Orion Research Foundation grants EUR 1,112,000 for research in 2024
GlobeNewswire 2022-03-24 Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
GlobeNewswire 2022-02-18 Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
GlobeNewswire 2022-02-17 Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...
GlobeNewswire 2021-12-03 ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...
GlobeNewswire 2021-06-09 Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...
GlobeNewswire 2019-12-09 Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
GlobeNewswire 2019-07-31 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...
GlobeNewswire 2019-06-19 1,767 Orion Corporation A shares converted into B shares
GlobeNewswire 2019-06-11 Change in Orion Corporation's holding of treasury shares
GlobeNewswire 2019-06-06 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...
GlobeNewswire 2019-06-03 Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Sprint Corp...
GlobeNewswire 2019-05-31 2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
GlobeNewswire 2019-05-30 ORION NOTICE: Rosen, a Widely Recognized Law Firm, Reminds Orion Group Holdings, Inc. Investors of I...
GlobeNewswire 2019-05-30 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...
GlobeNewswire 2019-05-22 S DEADLINE ALERT: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit A...
GlobeNewswire 2019-05-22 ORN JUNE 10 DEADLINE:  Pawar Law Group Reminds Investors of Deadline in Securities Class Action Laws...
GlobeNewswire 2019-05-22 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...